DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for brain edema — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrain edema maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brain edema is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
In a 2011 mouse model of acetaminophen-induced acute liver failure, brain edema was linked to increased blood–brain barrier permeability and elevated serum tumour necrosis factor alpha. Electron microscopy showed tight junction disruptions, endothelial cell shrinkage, and increased vesicles. The tight junction protein occludin was significantly decreased. Intravenous injection of anti-TNFα-IgG (100 µg per mouse) two hours after acetaminophen prevented both the increase in permeability and the loss of occludin. The study concluded that TNFα plays a critical role in brain edema in this model, but the work was limited to mice and a single toxin-induced cause of liver failure.
A 2016 rat study of experimental head trauma tested cerebroventricular injection of albumin, mannitol, hypertonic sodium chloride, glycerin, and dextran (2 µl each, given 6, 12, and 24 hours after trauma). Compared with controls, albumin, mannitol, 3% NaCl, and glycerin produced dramatic increases in reduced glutathione levels (p < 0.001). Malondialdehyde, a marker of lipid peroxidation and brain edema, showed only a non-significant decreasing trend. Nitric oxide decreased only in the 3% NaCl group. The proinflammatory cytokine IL-1β decreased significantly in all treatment groups (p = 0.001), but TNFα levels did not differ significantly from controls. The authors reported substantial effects on brain edema treatment, but the study was small (nine rats per group) and used a stereotactic delivery route that is not standard clinical practice.
A 2024 bioinformatics analysis of human intracerebral haemorrhage datasets (GSE216607 and GSE206971) identified four genes—VASP, HCLS1, MSN, and EZR—as critical for tight junctions, with increased expression after haemorrhage. In a C57BL/6J mouse intracerebral haemorrhage model, qRT-PCR validated the upregulation of these genes. Drug screening suggested that testosterone enanthate, selenium, and LY 294002 might affect these tight junction-related genes, but no in vivo efficacy data were provided. The study remains a computational and exploratory analysis; no clinical trial or patient outcome data exist for these proposed targets.
Across these studies, the evidence for any drug reducing brain edema in humans is absent. The anti-TNFα antibody worked only in a mouse liver failure model. The hyperosmotic agents showed biochemical changes in rats but no survival or functional outcome data. The 2024 gene targets are untested in patients. What is missing is any randomised controlled trial in humans, adequate funding for such trials, and a clear patient stratification strategy that accounts for the different causes of brain edema (trauma, liver failure, haemorrhage) and the timing of intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
European Journal of Gastroenterology & Hepatology · 2011 · 35 citations
AbstractOBJECTIVES: Cerebral edema is a major cause of death during acute liver failure (ALF), but the exact mechanism of this condition is still not entirely clear. The aim of this study was to investigate the role of tumor necrosis factor α (TNFα) in changing the permeability of the blood-brain barrier (BBB) during acetaminophen (APAP)-induced ALF. MATERIALS AND METHODS: ALF animal models were generated by administering APAP. Anti-TNFα-IgG was intravenously injected (100 μg/mouse) 2 h after administration of APAP. We investigated BBB permeability with Evans blue staining, and structure with electron microscopy. RESULTS: BBB permeability increased in APAP-induced ALF mice and correlated with elevated serum TNFα levels. Electron microscopy of mouse brain tissues revealed tight junction (TJ) disruptions and endothelial cell shrinkage, as well as increased vesicles and vacuoles. In addition, the expression of the TJ-associated protein, occludin, was significantly decreased in APAP-induced ALF mice. Changes in BBB permeability and occludin expression could be prevented by administering anti-TNFα-IgG 2 h after APAP challenge. CONCLUSION: TNFα plays a critical role in the development of brain edema in APAP-induced ALF. Increased BBB permeability may be due to the loss of the TJ-associated protein occludin.
Turkish Neurosurgery · 2016 · 3 citations · open access
The effects of stereotactic cerebroventricular administration of albumin, mannitol, hypertonic sodium chloride, glycerin and dextran in rats with experimental brain edema
AbstractAIM: To evaluate the effects of cerebroventricular administration of hyperoncotic/hyperosmotic agents on edematous brain tissue in rats with experimental head trauma. MATERIAL AND METHODS: The study included 54 female Sprague-Dawley rats with weights ranging between 200 and 250 g. Six experimental groups were examined with each group containing 9 rats. All rats were exposed to head trauma, and treatment groups were administered 2 µl of one of the drugs (albumin, mannitol, hypertonic sodium chloride (NaCl), glycerin and dextran) 6, 12 and 24 hours after the trauma via the cerebroventricular route and using a stereotactic device. Rats were sacrificed 48 hours after the trauma, and brain tissues were extracted without damage. Biochemical analyses including reduced glutathione (GSH), nitric oxide (NO), malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), and interleukin 1 beta (IL-1β) were performed on the injured left hemisphere. RESULTS: Compared with the control group, the albumin, mannitol, 3% NaCl and glycerin treatment groups revealed dramatic increases in GSH levels (p < 0.001). Levels of MDA, which is the end-product of brain edema and lipid peroxidation, failed to show a statistically significant decrease, but there was a decreasing trend observed in the inter-group comparisons. NO levels were also decreased in the 3% NaCl treatment group. An analysis of TNF-α and IL-1β, two proinflammatory cytokines associated with the trauma, revealed that IL-1β decreased significantly in all treatment groups (p=0.001), whereas no significant difference was detected in TNF-α levels. CONCLUSION: Cerebroventricular administration of hyperoncotic/hyperosmotic agents provides substantial effects on the treatment of brain edema.
Brain Hemorrhages · 2024 · 1 citations · open access
VASP, HCLS1, MSN, and EZR: Key molecular beacons in the pathophysiology of perihematomal edema Post-Intracerebral hemorrhage
AbstractPerihematomal edema (PHE) is one of the significant secondary cerebral damages, with the blood–brain barrier's integrity playing a pivotal role in its progression. Strengthening tight junction (TJ) proteins enhances blood–brain barrier integrity, yet the complex genetics behind brain edema remain not fully understood. Our research endeavors to uncover pivotal genes and their roles in brain edema following cerebral hemorrhage, and to investigate potential treatment strategies. By analyzing intracerebral hemorrhage (ICH) and control samples using the GSE216607 and GSE206971 datasets, we identified differentially expressed genes. Cross-referencing with the KEGG database, we aligned these genes with those related to tight junctions. Extensive enrichment analysis and protein interactions were performed to examine the expression and clinical significance of the identified genes. Our study employed the C57BL/6J mouse ICH model and qRT-PCR for key gene validation. Notably, VASP, HCLS1, MSN, and EZR, critical for tight junctions, showed increased expression post-ICH, emphasizing their significance in BBB upkeep and PHE progression. Drug validation indicated potential therapeutic effects of Testosterone enanthate, SELENIUM, and LY 294002 on tight junction-related genes. This study sheds light on the potential involvement of these genes in brain edema progression post-ICH, offering promising therapeutic targets. Further research is needed for deeper understanding.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
